These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

828 related items for PubMed ID: 17366349

  • 41. Neuroleptic malignant syndrome: a case report.
    Fekadu A, Wakwoya A.
    Ethiop Med J; 1999 Jul; 37(3):195-8. PubMed ID: 11957317
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Probable association between ziprasidone and worsening hypertension.
    Villanueva N, Markham-Abedi C, McNeely C, Diaz FJ, de Leon J.
    Pharmacotherapy; 2006 Sep; 26(9):1352-7. PubMed ID: 16945059
    [Abstract] [Full Text] [Related]

  • 44. Adverse effects of summer amongst people with learning disabilities: neuroleptic malignant syndrome.
    Fitzgerald B, Middleton JK, Cooper SA.
    J Intellect Disabil Res; 1997 Jun; 41 ( Pt 3)():273-7. PubMed ID: 9219078
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Atypical neuroleptic malignant syndrome in patients treated with aripiprazole and clozapine: a case-series study and short review.
    Tseng PT, Chang YC, Chang CH, Wang HY, Cheng YS, Wu CK, Chen YW, Chung W.
    Int J Psychiatry Med; 2015 Jun; 49(1):35-43. PubMed ID: 25838319
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia.
    Arango C, Gómez-Beneyto M, Brenlla J, Gastó C, Sarramea-Crespo F, Chamorro L, Masramon X, Díez T, ZIS Study Group.
    Eur Neuropsychopharmacol; 2007 Jun; 17(6-7):456-63. PubMed ID: 17234389
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. [Catatonia, malignant neuroleptic syndrome and myositis ossificans].
    Topka H, Buchkremer G.
    Nervenarzt; 1996 May; 67(5):413-7. PubMed ID: 9005354
    [Abstract] [Full Text] [Related]

  • 52. Switching among antipsychotics in everyday clinical practice: focus on ziprasidone.
    Rossi A, Cañas F, Fagiolini A, Larmo I, Levy P, Montes JM, Papageorgiou G, Sturlason R, Zink M, Correll CU.
    Postgrad Med; 2011 Jan; 123(1):135-59. PubMed ID: 21293094
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. [Ziprasidone. A new second-generation antipsychotic agent].
    Lublin HK.
    Ugeskr Laeger; 2004 Mar 29; 166(14):1334-9. PubMed ID: 15101124
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Urticaria and angio-oedema due to ziprasidone.
    Akkaya C, Sarandol A, Aydogan K, Kirli S.
    J Psychopharmacol; 2007 Jul 29; 21(5):550-2. PubMed ID: 17446198
    [Abstract] [Full Text] [Related]

  • 58. Ziprasidone-induced hypersensitivity syndrome in an aged schizophrenia patient.
    Tsai CF, Tsai SJ, Hwang JP.
    Int J Geriatr Psychiatry; 2005 Aug 29; 20(8):797-9. PubMed ID: 16035110
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations.
    Picard LS, Lindsay S, Strawn JR, Kaneria RM, Patel NC, Keck PE.
    Pharmacotherapy; 2008 Apr 29; 28(4):530-5. PubMed ID: 18363536
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 42.